Cite
HARVARD Citation
Buske, C. et al. (2022). Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. Journal of clinical oncology. 40 (1), pp. 52-62. [Online].